U.S. Direct-to-Consumer Genetic Testing Market Analysis

U.S. Direct-to-Consumer Genetic Testing Market Analysis

With respect to test, the U.S. DTC genetic testing market share from predictive testing segment is poised to grow at a 13% CAGR through 2023 to 2032. The increasing incidence rate of chronic and genetic diseases in the region is likely to drive the segment progression. The disease load of inherited ailments such as cystic fibrosis, sickle cell anemia, thalassemia, and hemophilia in growing at a rapid pace in the U.S., creating a higher growth impetus for the DTC test sector.
 

On the basis of technology, the U.S. direct-to-consumer genetic testing market share from the single nucleotide polymorphism (SNP) chips segment is poised to grow at over 11.5% CAGR from 2023 to 2032. Substantial usage of single nucleotide polymorphism (SNP) chips in genome sequencing is expected to drive the segment revenues. These chips study gene sequences at a particular resolution and present a detailed analysis of the defective genes that may cause certain disorders in the future. The SNP technology is capable of analysing changes in a single letter, which boosts the efficiency of tests. In fact, SNP chips used for the diagnosis of hereditary cancers have detected 1300 mutations in BRCA2 genes.
 

Based on distribution channel, the U.S. DTC genetic testing market size from online platforms was valued at over USD 1.2 billion in 2022, driven by increasing consumer preference for online shopping and the popularity of tests such as 23andme and ancestry. Meanwhile, rising healthcare investments in the region is also fostering the market outlook.
 

With increasing per capita income and rising consumer awareness, leading players in the field are focusing on consolidating a presence on e-commerce and online retail platforms to make their products more easily accessible to customers.